Ciliatech, a pioneering medical technology company focused on glaucoma treatments, has announced that its groundbreaking glaucoma implant, the Cilioscleral Interposition Device (CID), received a favorable third-party review for its effectiveness in treating both open and narrow-angle forms of glaucoma. The endorsement came during a presentation by Dr. Leon Au at the 12th International Congress of Glaucoma Surgery (ICGS) held in Abu Dhabi, highlighting CID’s robust potential as a treatment option for glaucoma.
Dr. Leon Au, a leading consultant ophthalmologist and eye surgeon from the Manchester Royal Eye Hospital in the UK, presented the first independent observations of the CID at ICGS. His talk, titled ‘Looking into the pipeline: New Devices,’ detailed the early three-year clinical results of the first- and second-generation CID implants that have been under investigation since 2021. According to Dr. Au, “Ciliatech’s device is a significant breakthrough. It allows for the placement of a suprachoroidal device without penetrating the anterior chamber of the eye, a procedure especially beneficial for angle closure glaucoma, where traditionally the patient’s lens would need to be removed.”
Glaucoma Implant CID Shows Promising 18-Month Efficacy Results
A poster presented by Dr. Lilit Voskanyan, a principal investigator and head of the glaucoma department at the Malayan Center in Yerevan, showcased CID’s effectiveness over 18 months. Titled ‘18-Month Outcomes of CID SV-22, a novel Cilioscleral Interposition Device for Patients with Open-Angle and Narrow-Angle Glaucoma,’ the poster reported a ‘statistically and clinically meaningful’ 37% reduction in baseline Intraocular Pressure (IOP) and highlighted that up to 80% of patients were able to discontinue IOP-lowering medications.
The results affirmed CID’s efficacy in both Primary Open Angle Glaucoma (POAG) and Primary Narrow Angle Glaucoma (PNAG), with an impressive safety profile evidenced by the absence of filtering blebs and no need for adjunctive therapies or additional surgeries.
Olivier Benoit, CEO of Ciliatech, expressed his enthusiasm about the independent validation of the CID, stating, “For the first time, a world-renowned glaucoma surgeon has independently reviewed our CID device in person and presented these observations to a global audience of glaucoma specialists. This is a pivotal moment for us as we continue to push forward with our innovative therapies that promise to significantly improve the management of glaucoma.”
Glaucoma Implant CID Features Innovative, Non-Invasive Approach at ICGS 2024
The presentation and poster at the ICGS 2024 reflect Ciliatech’s commitment to advancing glaucoma treatment through innovative surgical techniques. The CID implant’s unique surgical approach—placing the device externally into the supraciliary space without entering the eye’s anterior chamber—sets it apart from other glaucoma procedures, offering a less invasive option with potential benefits for a broader range of patients.
Ciliatech continues to work closely with regulatory bodies to secure approvals for CID, aiming for commercial launches in key global markets. The company’s ongoing SAFARI clinical trial series, which includes a planned fifth study to commence later this year, underscores its proactive approach to validating and enhancing the CID’s therapeutic efficacy and safety.
Resource: Ciliatech, April 24, 2024
This article has been prepared with the assistance of AI and reviewed by an editor. For more details, please refer to our Terms and Conditions. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author.
